KFA
ABBV icon

Krane Funds Advisors’s AbbVie ABBV Stock Holding History

Krane Funds Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$748K Sell
2,974
-444
-13% -$95.5K 0.03% 108
2026
Q1 		$706K Buy
3,418
+1,452
+74% +$322K 0.03% 109
2025
Q4 		$449K Buy
1,966
+269
+16% +$61.3K 0.01% 112
2025
Q3 		$388K Sell
1,697
-546
-24% -$111K 0.01% 113
2025
Q2 		$416K Buy
2,243
+584
+35% +$109K 0.02% 80
2025
Q1 		$348K Sell
1,659
-338
-17% -$65.7K 0.01% 82
2024
Q4 		$355K Sell
1,997
-185
-8% -$34K 0.01% 72
2024
Q3 		$431K Buy
2,182
+65
+3% +$12.1K 0.02% 58
2024
Q2 		$363K Sell
2,117
-148
-7% -$24.5K 0.02% 73
2024
Q1 		$407K Sell
2,265
-694
-23% -$120K 0.02% 80
2023
Q4 		$459K Buy
2,959
+1,142
+63% +$166K 0.02% 74
2023
Q3 		$271K Sell
1,817
-3,161
-63% -$464K 0.01% 97
2023
Q2 		$671K Buy
4,978
+1,469
+42% +$215K 0.04% 33
2023
Q1 		$566K Buy
+3,509
New +$536K 0.03% 55
2022
Q3 		– Sell
-1,866
Closed -$286K – 118
2022
Q2 		$286K Buy
+1,866
New +$285K 0.01% 172

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Krane Funds Advisors's ABBV Position: Q2 2026 in Review

Krane Funds Advisors reduced its AbbVie (ABBV) stake by 13% in Q2 2026, selling an estimated $95.5K and leaving 2,974 shares worth $748K. The position accounts for 0.03% of the portfolio, ranked #108.

Krane Funds Advisors first reported a position in ABBV in Q2 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Krane Funds Advisors held 2,974 shares of AbbVie worth $748K as of Q2 2026.
  • Krane Funds Advisors sold 444 AbbVie shares in Q2 2026, an estimated $95.5K.
  • AbbVie made up 0.03% of Krane Funds Advisors's portfolio in Q2 2026, its #108 holding.
  • Krane Funds Advisors first reported a position in AbbVie in Q2 2022 and has held it in 15 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Krane Funds Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.